Share on StockTwits

Aldeyra Therapeutics (NASDAQ:ALDX) Director Martin Joseph Joyce purchased 1,000 shares of the stock on the open market in a transaction dated Thursday, August 7th. The stock was purchased at an average cost of $3.95 per share, with a total value of $3,950.00. Following the completion of the acquisition, the director now directly owns 13,500 shares of the company’s stock, valued at approximately $53,325. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Separately, analysts at Aegis initiated coverage on shares of Aldeyra Therapeutics in a research note on Thursday, June 19th. They set a “buy” rating and a $35.00 price target on the stock.

Aldeyra Therapeutics (NASDAQ:ALDX) traded up 8.07% on Friday, hitting $4.1499. 5,084 shares of the company’s stock traded hands. Aldeyra Therapeutics has a one year low of $3.00 and a one year high of $8.222. The stock’s 50-day moving average is $5.32 and its 200-day moving average is $6.00. The company’s market cap is $25.9 million.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Monday, August 4th. The company reported ($1.56) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.53) by $1.03. Analysts expect that Aldeyra Therapeutics will post $-1.49 EPS for the current fiscal year.

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) is a biotechnology company.

Receive News & Ratings for Aldeyra Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.